Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study

doi:10.3724/SP.J.1123.2019.01008

Abstract

Abstract:

A simple, sensitive, and stable high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed and validated for the simultaneous determination of leucovorin and 5-methyltetrahydrofolate diastereomers in human plasma using methotrexate as the internal standard. The analytes and the internal standard were extracted from plasma samples by simple ultrafiltration centrifugation-based extraction. The separation was achieved on a chiral HSA column (150 mm×4 mm, 5 μm) using mobile phases containing 10 mmol pH 8.0 ammonium acetate and acetonitrile in gradient mode. The method showed good linearities in the ranges of 25-5000 μg/L and 12.5-3000 μg/L for leucovorin and 5-methyltetrahydrofolate diastereoisomers, respectively. The method was fully validated with respect to sensitivity, precision, accuracy, matrix effect, extraction recovery, and stability of analytes under various conditions. The method was successfully applied to a pharmacokinetic study of 125 mg/m² 6R,S-leucovorin and 62.5 mg/m² 6S-leucovorin. The results showed that the maximum observed concentrations (C_max) of 6S-leucovorin and L-5-methyltetrahydrofolate were (3137.917±408.837) and (1679.633±244.132) μg/L, respectively, and the areas under the curve from the time of dosing to the last measurable concentration (AUC_0-t) were (7504.883±1185.101) and (14001.214±2868.949) μg/L in the 125 mg/m² 6R,S-leucovorin dose group. The C_max values of 6S-leucovorin and L-5-methyltetrahydrofolate were (3187.917±387.298) and (1739.204±224.755) μg/L, respectively, and AUC_0-t values were (7426.664±854.825) and (14884.331±1843.353) μg/L in the 62.5 mg/m² 6S-leucovorin dose group. There were no significant diffe-rences in the main pharmacokinetic parameters between the two dose groups, and the pharmacokinetic characteristics as well as the rate and extent of absorption were consistent. This method can provide technical support for future bioequivalence studies of sodium leucovorin.

Key words: chiral separation, high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), leucovorin (LV), pharmacokinetics, ultrafiltration centrifugation

CLC Number:

O658

XU Chenfeng, HUI Wenkai, SUN Lili, GAO Qianqian, ZOU Qiaogen. Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study[J]. Chinese Journal of Chromatography, 2019, 37(6): 581-588.

References

[1] Flombaum C D, Liu D Z, Yan S Q, et al. Pharmacotherapy, 2018, 38(7):714
[2] Qian X, Li L K, Wang Q C, et al. China Journal of Hospital Pharmacy, 2016, 36(18):1613 钱鑫, 李龙宽, 王清忱, 等. 中国医院药学杂志, 2016, 36(18):1613
[3] Li J, Xu R H, Xu J M, et al. Cancer Sci, 2017, 108(10):2045
[4] Newman E M, Straw J A, Doroshow J H, et al. Cancer Res, 1989, 49(20):5755
[5] Newman E M, Akman S A, Harrison J S, et al. Cancer Res, 1992, 52(9):2408
[6] Blakley R L. The Biochemistry of Folic Acid and Related Pteridines. London:North -Holland Publishing Co, 1969:82
[7] Cosulich D B, Smith J M, Broquist R M. J Am Chem Soc, 1952, 74:4215
[8] Deng F L, Liu B M, Rao J M, et al. Chinses Journal of Analytical Chemistry, 2005, 33(7):996 邓富良, 陈本美, 饶均明, 等. 分析化学, 2005, 33(7):996
[9] Lu L H, Liu L. Journal of China Pharmaceutical university, 2008, 39(6):530 吕立华, 刘黎. 中国药科大学学报, 2008, 39(6):530
[10] Schleyer E, Reinhardt J, Reinhardt M, et al. J Chromatogr B, 1995, 669(2):319
[11] Liu K, Dai X, Zhong D, et al. J Chromatogr B, 2009, 877(10):902
[12] Silan L, Jadaud P, Whitfield L R, et al. J Chromatogr B, 1990, 532(2):227
[13] Pan H, Ji C, Tong Y, et al. Chinese Journal of New Drugs and Clinical Remedies, 2014, 33(10):760 潘虹, 季程, 童颖, 等. 中国新药与临床杂志, 2014, 33(10):760
[14] Dun B, Liu H C. Chinese Journal of Clinical Pharmacology, 2005, 21(1):66 顿彬, 刘会臣. 中国临床药理学杂志, 2005, 21(1):66
[15] Rui J Z, Wu J F, Pang X D, et al. Chinese Pharmacological Bulletin, 1998, 14(1):14 芮建中, 吴锦芳, 庞晓东, 等. 中国药理学通报, 1998, 14(1):14
[16] Zhang Y Y, Li L, Xing X Q, et al. Chinese Journal of Chromatography, 2018, 36(12):1290 张颖怡, 李良, 刑旭琴, 等. 色谱, 2018, 36(12):1290
[17] Zhan L N, Chen Q, Gu S Q, et al. Chinese Journal of Chromatography, 2017, 35(4):405 詹丽娜, 陈沁, 古淑青, 等. 色谱, 2017, 35(4):405
[18] Ccedil E M, Nenni M, Altinoz S. Pharm Chem J, 2016, 50(4):275
[19] Wang X Y, Li C, Du C H, et al. Bioanalysis, 2017, 9(7):579
[20] U. S. Food & Drug Administration. Guidance for Industry:Bioanalytical Method Validation. (2018-05-21)[2018-07-24]. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf